Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-Aminoimidazole-4-carboxamide is an imidazole derivative that serves as a crucial precursor in the de novo biosynthesis of purines, including adenine and guanine. It is also recognized as a metabolite of certain antineoplastic agents, such as BIC and DIC. The compound, or its ribonucleotide form, acts as a condensation agent in the preparation of nucleosides and nucleotides. Historically, when compounded with orotic acid, it has been used to treat liver diseases. It has also been investigated for potential applications in allergic rhinitis and pediatric indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-Aminoimidazole-4-carboxamide.